- Home
- MPB vs HUMA Comparison
MPB vs HUMA Comparison
Compare MPB & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MPB | HUMA |
|---|---|---|
| Founded | 1868 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.9M | 236.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MPB | HUMA |
|---|---|---|
| Price | $31.04 | $0.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $37.00 | $10.13 |
| AVG Volume (30 Days) | 86.8K | ★ 4.5M |
| Earning Date | 01-21-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $208,869,000.00 | $1,571,000.00 |
| Revenue This Year | $26.19 | N/A |
| Revenue Next Year | $28.25 | $698.97 |
| P/E Ratio | $12.96 | ★ N/A |
| Revenue Growth | ★ 20.73 | N/A |
| 52 Week Low | $22.50 | $0.99 |
| 52 Week High | $33.24 | $5.48 |
Technical Indicators
Market Signals| Indicator | MPB | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 29.70 |
| Support Level | $31.64 | $1.04 |
| Resistance Level | $33.24 | $1.17 |
| Average True Range (ATR) | 0.58 | 0.08 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 2.21 | 10.58 |
Price Performance
Historical ComparisonAbout MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.